Skip to main content
Erschienen in: Uro-News 11/2016

05.11.2016 | Hodentumoren | Zertifizierte Fortbildung

Maligne Keimzelltumoren

Aktuelle Therapieempfehlungen bei Seminomen

verfasst von: Dr. med. Michael Hartmann

Erschienen in: Uro-News | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Fast 95 % der Hodenmalignome sind Keimzelltumoren. Traten in früheren Jahren Nichtseminome häufiger auf als Seminome, hat sich das Verhältnis seit 1990 umgekehrt. Angestiegen ist neben der Häufigkeit der Keimzelltumoren auch das Alter der Patienten mit Seminomen bei Erkrankungsbeginn. Dieses kann bei der Therapiewahl neben Tumorstadium, Risikofaktoren und weiteren Kriterien, wie zum Beispiel dem zeitgerechten Markerabfall nach Ablatio testis, einbezogen werden.
Literatur
1.
Zurück zum Zitat Mead GM, Stenning SP. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol). 1997,9:207–9.CrossRef Mead GM, Stenning SP. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol). 1997,9:207–9.CrossRef
2.
Zurück zum Zitat Krege S. Therapie der Seminome im klinischen Stadium I und IIA/B. In: Michel MS, Hrsg. Die Urologie. Berlin, Heidelberg: Springer-Verlag; 2016. S. 1749–54. Krege S. Therapie der Seminome im klinischen Stadium I und IIA/B. In: Michel MS, Hrsg. Die Urologie. Berlin, Heidelberg: Springer-Verlag; 2016. S. 1749–54.
3.
Zurück zum Zitat Eble JN, et al. Pathology and genetics of tumours of the urinary system and male genital organs - WHO histological classification of testis tumours. IARC Press. 2004;218:212. Eble JN, et al. Pathology and genetics of tumours of the urinary system and male genital organs - WHO histological classification of testis tumours. IARC Press. 2004;218:212.
4.
Zurück zum Zitat Klein EA. Tumor markers in testis cancer. Urol Clin North Am. 1993;20:67–73.PubMed Klein EA. Tumor markers in testis cancer. Urol Clin North Am. 1993;20:67–73.PubMed
5.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind CH, International Union against Cancer (UICC). TNM classification of malignant tumors. Chichester, Hoboken: Wiley-Blackwell; 2010. Sobin LH, Gospodarowicz MK, Wittekind CH, International Union against Cancer (UICC). TNM classification of malignant tumors. Chichester, Hoboken: Wiley-Blackwell; 2010.
6.
Zurück zum Zitat Leibovitch L, Foster RS, Kopecky KK, Donohue JP. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol. 1995;154:1759–63.CrossRefPubMed Leibovitch L, Foster RS, Kopecky KK, Donohue JP. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol. 1995;154:1759–63.CrossRefPubMed
7.
Zurück zum Zitat Albers P, Albrecht W, Algaba F, et al. Guidelines on Testicular Cancer: 2015 Update. Euro Urol. 2015;68:1054–68.CrossRef Albers P, Albrecht W, Algaba F, et al. Guidelines on Testicular Cancer: 2015 Update. Euro Urol. 2015;68:1054–68.CrossRef
8.
Zurück zum Zitat Dieckmann KP, Kulejewski M, Heinemann V, Loy V. Testicular biopsy for early cancer detection — objectives, technique and controversies. Int J Androl. 2011;34:e7–13.CrossRefPubMed Dieckmann KP, Kulejewski M, Heinemann V, Loy V. Testicular biopsy for early cancer detection — objectives, technique and controversies. Int J Androl. 2011;34:e7–13.CrossRefPubMed
9.
Zurück zum Zitat Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24:878–88.CrossRefPubMed Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24:878–88.CrossRefPubMed
10.
Zurück zum Zitat Mortensen MS, Lauritsen J, Gundgaard MG, Agerbæk M, Holm NV, Christensen IJ, von der Maase H, Daugaard G. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014;66:1172–8.CrossRefPubMed Mortensen MS, Lauritsen J, Gundgaard MG, Agerbæk M, Holm NV, Christensen IJ, von der Maase H, Daugaard G. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014;66:1172–8.CrossRefPubMed
11.
Zurück zum Zitat Shelley MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review. Cancer Treat Rev. 2002;28:237–53.CrossRefPubMed Shelley MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review. Cancer Treat Rev. 2002;28:237–53.CrossRefPubMed
12.
Zurück zum Zitat Chung P, Daugaard G, Tyldesley S, et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med. 2015;4:155–60.CrossRefPubMed Chung P, Daugaard G, Tyldesley S, et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med. 2015;4:155–60.CrossRefPubMed
13.
Zurück zum Zitat Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29:957–62.CrossRefPubMed Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29:957–62.CrossRefPubMed
14.
Zurück zum Zitat Aparicio J, Maroto P, del Muro XG, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011;29:4677–81.CrossRefPubMed Aparicio J, Maroto P, del Muro XG, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011;29:4677–81.CrossRefPubMed
15.
Zurück zum Zitat Dieckmann KP, Dralle-Filiz I, Matthies C, et al. Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol. 2016;142:1599–607.CrossRefPubMedPubMedCentral Dieckmann KP, Dralle-Filiz I, Matthies C, et al. Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol. 2016;142:1599–607.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Tandstad T, Ståhl O, Dahl O, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommadtions inplementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27:1299–304.CrossRefPubMed Tandstad T, Ståhl O, Dahl O, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommadtions inplementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27:1299–304.CrossRefPubMed
17.
Zurück zum Zitat Giannatempo P, Greco T, Mariani L, et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systemic review and meta-analysis of patient outcomes. Ann Oncol. 2015;26:657–68.CrossRefPubMed Giannatempo P, Greco T, Mariani L, et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systemic review and meta-analysis of patient outcomes. Ann Oncol. 2015;26:657–68.CrossRefPubMed
18.
Zurück zum Zitat Chung PW, Gospodarowicz MK, Panzarella T, et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol. 2004;45:754–9.CrossRefPubMed Chung PW, Gospodarowicz MK, Panzarella T, et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol. 2004;45:754–9.CrossRefPubMed
19.
Zurück zum Zitat Gundgaard MG, Lauritsen J, Mortensen MS, et al. Germ cell cancer (GCC: long-term survival after treatment with bleomycin (B), etoposide (E) and cisplatin (C) in a large cohort. J Clin Oncol. 31, 2013 (suppl; abstr 4533). Gundgaard MG, Lauritsen J, Mortensen MS, et al. Germ cell cancer (GCC: long-term survival after treatment with bleomycin (B), etoposide (E) and cisplatin (C) in a large cohort. J Clin Oncol. 31, 2013 (suppl; abstr 4533).
20.
Zurück zum Zitat Bachner M, Loriot Y, Gross-Goupil M, et al. 2-18-fluorodeoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol. 2012;23:59–64.CrossRefPubMed Bachner M, Loriot Y, Gross-Goupil M, et al. 2-18-fluorodeoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol. 2012;23:59–64.CrossRefPubMed
21.
Zurück zum Zitat Puc H, Heelan R, Mazumar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1996;14:454–60.PubMed Puc H, Heelan R, Mazumar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1996;14:454–60.PubMed
Metadaten
Titel
Maligne Keimzelltumoren
Aktuelle Therapieempfehlungen bei Seminomen
verfasst von
Dr. med. Michael Hartmann
Publikationsdatum
05.11.2016
Verlag
Springer Medizin
Erschienen in
Uro-News / Ausgabe 11/2016
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-016-0916-1

Weitere Artikel der Ausgabe 11/2016

Uro-News 11/2016 Zur Ausgabe